Spain joins Greece with big drug-price cuts

In the latest blow to drugmakers from Europe's economic woes, Spain is cutting the prices of numerous meds in hopes of reducing what the public health system spends on prescription drugs by as much as 23 percent. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.